Dynamic changes and clinical significance of LXA4 in the perioperative period of cardiopulmonary bypass

Dynamic changes and clinical significance of LXA4 in the perioperative period of cardiopulmonary bypass (Free)



Dynamic changes in lipoxin A4 (LXA4) in child patients with congenital heart disease (CHD), in the perioperative period of cardiopulmonary bypass (CPB) were studied. Peripheral blood was collected from 16 child patients (CPB group) before operation (Tc), after operation (T0), at 1 day after operation (T1), at 3 days after operation (T3), and at 7 days after operation (T7); and from 17 children with no CHD (control group). The level of LXA4 in peripheral blood was detected via enzyme-linked immunosorbent assay (ELISA). Clinical data of the child patients were collected. The white blood cell (WBC) count, the proportion of neutrophils (N%) and high-sensitivity C-reactive protein (hs-CRP) levels were also detected, followed by statistical analysis. The plasma LXA4 levels in CPB group at Tc were significantly lower compared to that in the control group (P<0.01). In CPB group, the level of LXA4 showed an increasing trend at T0, WBC and hs-CRP were transiently increased at T0 and increased most significantly at T1. N% was obviously increased at T0 compared to that at Tc and was still significantly higher at T7 compared to that at Tc. The CPB time and aortic clamping time were positively correlated with the time in the Pediatric Intensive Care Unit (PICU), the application time of ventilator, and the hs-CRP level at T0. The LXA4 level at each time-point had no correlation with other indexes. In conclusion, the inflammatory response after CPB increases the synthesis of LXA4 with an anti-inflammatory effect, but LXA4 cannot be used as a sensitive index for monitoring inflammation.

Keywords: congenital heart disease, cardiopulmonary bypass, lipoxin A4


Congenital heart disease (CHD) is a common congenital developmental malformation in pediatrics. Cardiopulmonary bypass (CPB) is a representative technique of cardiac surgery, and it has been increasingly improved and widely popularized in recent years. However, CPB is an invasive treatment, whose postoperative complications, such as postoperative infection, low cardiac output syndrome, heart failure, arrhythmia and bleeding, should be paid enough attention to. The surgical trauma, low temperature, ischemia reperfusion and the contact with the surface of artificial materials, such as the artificial tube during CPB, can activate the immune system in the body, lead to activation of inflammatory cells, coagulation system, complement system, white blood cells (WBCs) and platelets, and release inflammatory factors (13). Lipoxin A4 (LXA4), as an important endogenous anti-inflammatory mediator, can reduce the production of inflammatory factors and inhibit the activation and chemotaxis of neutrophils (4). This study compared the LXA4 levels between child patients with CHD and non-CHD children, observed the dynamic changes of LXA4 in the perioperative period of CPB, and analyzed its correlation with blood routine indexes, high-sensitivity C-reactive protein (hs-CRP) and other clinical indexes, so as to find the correlation between LXA4 and the inflammatory response of CHD.

Recent Stories
FREE: The Case for the Anesthesiologist-Informaticist.

FREE: Robotic Cardiac Surgery in Europe: Status 2020.

FREE: Efficacy of Prothrombin Complex Concentrate (PCC) versus Fresh Frozen Plasma (FFP) in Reducing Perioperative Blood Loss in Cardiac Surgery: Study Protocol for A Non-Inferiority, Randomised Controlled Trial.

AmSECT Membership Eligibility

An Active Member shall be any perfusionist active in the practice of extracorporeal circulation technology. There are also opportunities to become a Transitional Active Member for those less than a year removed from graduation from an approved accredited training program. Other options include; an Associate Membership, International Membership, Perioperative Blood Management Clinician Membership, and Student Membership.

Click Here to Learn More

Looking for Employment Opportunities?

AmSECT members may post an available position for a perfusion specialty at your institution or firm.

Non-members may also post positions free of charge, to be reviewed by National Headquarters prior to posting.

Members - Click to Post a Position
Non-Members - Click to Post a Position

Contact AmSECT

AmSECT National Headquarters
330 N Wabash Ave, Suite 2000
Chicago, IL 60611

  Phone: (312) 321-5156
  Fax: (312) 673-6656
  Email: amsect@amsect.org

AmSECT © 2022 | View Privacy Policy | Site Map